

****Published September 2021****

MarketVIEW: Congenital cytomegalovirus vaccines (CAT: VAMV014)

Product Name	:	MarketVIEW: Congenital cytomegalovirus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (>175 slides.pdf) + forecast model(s) (.xls)
Therapeutic Area	:	Congenital cytomegalovirus vaccines
Publication date	:	September 2021
Catalogue No	:	VAMV014

Background

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the global population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher, even at younger ages. Usually, CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV positive individuals, transplants (HSCT/SOT) the virus can reactivate and cause severe disease outcomes in the lungs (pneumonia) and other organs. CMV infection is also a significant concern in the neonate after transmission from a pregnant women pre- or post- partum. It is estimated that ~20-40,000 US infants (1 in 200) is born each year with **congenital CMV infection** and, of those ~8,000 develop neurological sequelae such as hearing loss, intellectual disability, psychomotor delay, speech and language disabilities. CMV is the most common cause of birth defects and childhood disabilities.

This **MarketVIEW** product is composed of an Executive presentation (.pdf) and MS-Excel forecast (.xls) which appraises the potential commercial value of cytomegalovirus congenital vaccines across the public and private sector of 25 major Western and Emerging (ROW) markets to 2040¹. The forecast model can explore the impact of different variables such as: vaccine population targeting strategies, vaccinee CMV serostatus, vaccine price and coverage benchmarks. The analysis includes an up-to-date review of disease epidemiology, treatment and management along with latest mathematical modelling studies. A full review of competitor programs is discussed with a focus on **Merck & Co (V160)**, **Moderna Therapeutics (mRNA-1647)** and other competitors.

¹ Some EU markets are rolled into an 'Other EU' grouping

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Congenital cytomegalovirus vaccines in each respective market. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:

Published September 2021 (CAT No: VAMV014)

****This product is a [summary presentation \(.pdf\)](#), [an MS-workbook \(.xls\)](#)

Contents – Summary presentation (.pdf) 

Contents

Author's notes

Executive summary

[SECTION 1] Cytomegalovirus: disease background

[SECTION 2] Cytomegalovirus: focusing on the virus

[SECTION 3] Cytomegalovirus: diagnostics and treatment

[SECTION 4] Cytomegalovirus: review of epidemiology

[SECTION 5] Cytomegalovirus: summary of vaccine development, current R&D

[SECTION 6] Cytomegalovirus: review of vaccine strategies

[SECTION 7] Cytomegalovirus vaccines: modelling commercial potential

[SECTION 8] Cytomegalovirus vaccines: backup and source material

References/bibliography

About **VacZine Analytics**

Disclaimer

SNAPSHOT

PAGES: >175 slides fully referenced/sourced. Available in .pdf form

Contents – MS-Excel workbook (.xls) 

United States [4 target populations, public and private sector]

Canada

UK

France

Germany

Italy

Spain

Other Europe*

Brazil

India

China

Russia

Australia

Japan

South Korea

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$12,995.00**/ GBP **£9,410.00**# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – available upon request



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd
Warren (Carlton) House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049
E-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics ® and "the spiral logo" are UK Registered Trademarks, 2009



Since 2007

